Ser-Ap-Es

Hypertensive disease

Treatment

1 FDA approval

20 Active Studies for Ser-Ap-Es

What is Ser-Ap-Es

Reserpine

The Generic name of this drug

Treatment Summary

Hydrochlorothiazide is a medication used to treat swelling and high blood pressure. It is the most commonly prescribed thiazide diuretic, but its use is declining in favor of drugs such as angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. It was approved by the FDA in 1959 and is available in combination with other drugs.

Ser-Ap-Es

is the brand name

image of different drug pills on a surface

Ser-Ap-Es Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ser-Ap-Es

Reserpine

1960

8

Approved as Treatment by the FDA

Reserpine, also called Ser-Ap-Es, is approved by the FDA for 1 uses like Hypertensive disease .

Hypertensive disease

Used to treat High Blood Pressure (Hypertension) in combination with Polythiazide

Effectiveness

How Ser-Ap-Es Affects Patients

Hydrochlorothiazide helps the body get rid of more water through urine. The amount of hydrochlorothiazide taken will vary from person to person, but is usually between 25-100mg. People with weakened kidney or liver function should be especially careful when taking this drug.

How Ser-Ap-Es works in the body

Hydrochlorothiazide works by preventing the reabsorption of sodium and chloride, which causes water to be excreted from the body. This drug is transported from the blood into the cells lining the distal convoluted tubule in the kidneys, and then sent to the lumen of the tubule. Normally, sodium is reabsorbed into these cells and then pumped out into the bloodstream, causing a concentration gradient that encourages water to be reabsorbed. However, by blocking this reabsorption process, hydrochlorothiazide decreases the concentration gradient and reduces the amount of water that is reabsorbed by the body.

When to interrupt dosage

The suggested dosage of Ser-Ap-Es is contingent upon the identified condition, like Antepartum magnesium sulfate prevention, inadequately regulated blood pressure with single treatment and antihypertensives. The measure of dosage fluctuates in accordance with the technique of administration (e.g. Tablet, coated - Oral or Oral) recorded in the table beneath.

Condition

Dosage

Administration

Hypertensive disease

, 0.1 mg, 0.25 mg, 0.125 mg, 25.0 mg

Oral, Tablet, , Tablet - Oral, Tablet, coated, Tablet, coated - Oral

Warnings

There are 20 known major drug interactions with Ser-Ap-Es.

Common Ser-Ap-Es Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Reserpine.

Amifostine

Major

Reserpine may increase the hypotensive activities of Amifostine.

Amisulpride

Major

Reserpine may increase the antipsychotic activities of Amisulpride.

Astemizole

Major

The metabolism of Astemizole can be increased when combined with Reserpine.

Axitinib

Major

The serum concentration of Axitinib can be increased when it is combined with Reserpine.

Ser-Ap-Es Toxicity & Overdose Risk

The lowest toxic dose of hydrochlorothiazide in mice and rats has been found to be greater than 10g/kg. Those who overdose on the drug may experience low levels of potassium, chloride, and sodium in the blood. To treat these symptoms, supportive care including fluids and electrolytes is recommended, as well as vasopressors to treat hypotension and oxygen for respiratory impairment.

image of a doctor in a lab doing drug, clinical research

Ser-Ap-Es Novel Uses: Which Conditions Have a Clinical Trial Featuring Ser-Ap-Es?

158 active clinical trials are currently examining the potential of Ser-Ap-Es in providing relief from Cirrhosis, Edema and Congestive Heart Failure.

Condition

Clinical Trials

Trial Phases

Hypertensive disease

30 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Ser-Ap-Es Reviews: What are patients saying about Ser-Ap-Es?

5

Patient Review

1/29/2019

Ser-Ap-Es for High Blood Pressure

This drug has been the most effective in lowering my blood pressure to a normal level. I have tried many different drugs, but none of them have been as successful as this one.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ser-ap-es

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Ser-Ap-Es

Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Have you considered Ser-Ap-Es clinical trials?

We made a collection of clinical trials featuring Ser-Ap-Es, we think they might fit your search criteria.
Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Dietary Interventions for Hypertension

18+
All Sexes
Birmingham, AL

Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.

Waitlist Available
Has No Placebo

University of Alabama at Birmingham

Pankaj Arora, MD, FAHA

Have you considered Ser-Ap-Es clinical trials?

We made a collection of clinical trials featuring Ser-Ap-Es, we think they might fit your search criteria.
Go to Trials
Image of Wayne Health Mobile Units in Detroit, United States.

Text Message Reminders for High Blood Pressure

18+
All Sexes
Detroit, MI

This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region) Center (IRB# 100221MP2A), the purpose of which is to improve cardiometabolic health in two uniquely comparable cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center involves separate but related projects that aim to improve cardiometabolic health outcomes through better risk factor control for three chronic conditions that are of tremendous public health importance, (hypertension (HTN), heart failure, and coronary heart disease), all of which contribute significantly to premature death in Detroit and Cleveland. The present study is the prospective observational cohort component of ACHIEVE P1- EPI (Project 1) of the ACHIEVE GREATER Center and serves to characterize the population of patients with blood pressure (BP) levels above normal attending The Wayne Health Mobile Health Unit (MHU) events to better understand key factors (e.g., social determinants of health) that convey information about baseline BP levels and related clinical outcomes (e.g., follow-up clinic visits, BP control, and cardiovascular events).

Recruiting
Has No Placebo

Wayne Health Mobile Units

Steven J Korzeniewski, PhD

Image of University of Alberta in Edmonton, Canada.

Egg White Powder for High Blood Sugar and High Blood Pressure

18 - 70
All Sexes
Edmonton, Canada

Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides. This is a feasibility study to assess the acute effect of IRW in egg white hydrolysate for the management of high sugar and blood pressure. Participants at high risk of type 2 diabetes (T2D) or having T2D will undergo 4 consecutive treatments of 1 day each (randomly), during which they will consume a standardized breakfast with a smoothie containing different protein powders. Each treatment will be separated by a minimum of 1-week. Participants in the healthy control group will undergo 1 treatment only (one day).

Phase 1
Recruiting

University of Alberta

Jianping Wu, PhD

Image of Northern Arizona University in Flagstaff, United States.

CardioCare Quest for High Blood Pressure

18+
All Sexes
Flagstaff, AZ

This project aims to address healthcare disparities among Navaho people diagnosed with hypertension or prehypertension through three main objectives. Firstly, it identifies and shares insights on healthcare access disparities affecting Navaho individuals experiencing nonadherence to hypertension treatment. Secondly, the proposal develops a telehealth solution based on factors identified as knowledge gaps caused by healthcare access disparities in hypertension management; we will use the factors to design a series of engaging minigames that can be incorporated into the larger CardioCare Quest. These minigames will be co-designed with end users and clinicians. Finally, the proposal conducts comprehensive qualitative and quantitative assessments of user experiences, perceptions, and challenges with CardioCare Quest.

Recruiting
Has No Placebo

Northern Arizona University (+1 Sites)

Tochukwu Ikwunne, PhD

Have you considered Ser-Ap-Es clinical trials?

We made a collection of clinical trials featuring Ser-Ap-Es, we think they might fit your search criteria.
Go to Trials